The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Prevalence of MASLD
Timeframe: 2031
Progression/regression of MASLD
Timeframe: 2031
Predictors of MASLD progression/regression
Timeframe: 2031
Prevalence of advanced fibrosis
Timeframe: 2031
Progression/regression of advanced fibrosis
Timeframe: 2031
Predictors of fibrosis progression/regression
Timeframe: 2031
The association between physical activity and prevalent advanced fibrosis
Timeframe: 2031
The association between physical activity and risk of progressing to advanced fibrosis
Timeframe: 2031
Genetic factors associated with advanced fibrosis or MASLD progression/regression
Timeframe: 2031
Association between body composition and MASLD and/or liver fibrosis and progression/regression thereof
Timeframe: 2031